AIFAM Group LLC

aifaminc.com

VCMatch tracks AIFAM Group LLC as an investor focused on Biotech, Pharma, and Medtech companies and United States and Japan markets. Upload your deck to compare your startup against the full private matching profile.

Check Size

Not specified

Stages

Not specified

Focus Areas

Biotech, Pharma, Medtech

Geography

United States and Japan

Investment Thesis

AIFAM positions itself as a specialist in alternative investments, delivering institutional-grade, discretionary portfolio management and outsourced CIO services for primarily institutional clients. The firm emphasizes multi-strategy exposure across hedge funds, private equity, venture capital, private credit, secondaries and direct/co-investments, combining deep due diligence and a global (New York–Tokyo) platform with an industry-specific acceleration capability in life sciences.

Is AIFAM Group LLC right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

AIFAM Group LLC is most relevant for founders raising venture-backed rounds in Biotech, Pharma, Medtech, and Lending, especially across United States and Japan.

Focus statement

“Specializing in Alternative Investments and Strategies,” AIFAM invests across strategies in alternative investments (hedge funds, PE, venture capital, private credit, etc.) and serves as an Outsourced CIO / lead manager, managing custom discretionary portfolios for top-tier Japanese institutions while also operating a life-science acceleration program (TBAP).

Value Add

Dual-regulated, cross-border platform — team based in New York (Registered with the SEC) and Tokyo (Registered with the FSA) (site: “Team of 15+ is based in New York (Registered with the SEC) and in Tokyo (Registered with the FSA).”).
Institutional outsourced CIO / lead-manager capability — explicitly offers institutional delegated mandates: “Manages custom portfolios on a discretionary basis for top-tier Japanese institutions.”
Broad alternative strategy coverage — “We invest across strategies in alternative investments (hedge funds, PE, venture capital, private credit, etc.).”
Proven diligence and deal activity — public metrics show extensive experience: “Due Diligence cumulative 2,000+,” “# of Investments since inception 300+,” and “# of Secondary Deals since inception 40+.”
Life-science acceleration + investment bridge — operates the Triple Bridge Acceleration Program (TBAP), linking acceleration/consulting with investment activity in medical and life sciences.
Emphasis on lead/manager/co-investment roles — team bios repeatedly note responsibilities for fund due diligence, co-investment and direct investments, indicating an active, manager-driven approach.